Too busy to save time? Why IP teams can’t afford to wait on AI

In-house counsel from AstraZeneca, BAT and Novartis say that investing in AI now will pay off in time saved, but warn that tools remain prone to ‘confident’ errors, writes Marisa Woutersen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

7 in-house counsel tips for partnering with AI vendors

11 November 2025 Partnering with AI vendors can open doors for startups and small companies but it also brings serious risks. Experts at AI & IP Europe share key lessons on contracts, data ownership, ring-fencing, monitoring, and exit planning, as Marisa Woutersen reports.

Americas

‘AI curious’ counsel at AZ, Novartis weigh risks and benefits

10 December 2024 Corporate legal teams can embrace the AI revolution by encouraging experimentation and managing risks proactively, according to a recent panel featuring leading pharma counsel.

More features

AZ counsel warns: EU Bolar exemption is ‘painful’ for pharma innovators

Novartis moves to quash SCOTUS review of Entresto case

Pfizer beats Novo Nordisk in $10bn bidding war

‘I need them and they need me’: Regeneron counsel on what makes a strong law firm partnership

7 in-house counsel tips for partnering with AI vendors

Patent applications for bio-cosmetics double in five years

Sun Pharma and BMS lead 2025 ANDA litigation

Weil continues IP expansion as another litigator jumps from rival firm

Too busy to save time? Why IP teams can’t afford to wait on AI

More on this story

Editor's picks

Editor's picks

More features